Skip to main content

Peer Review reports

From: Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?

Original Submission
15 Mar 2021 Submitted Original manuscript
27 Aug 2021 Reviewed Reviewer Report - El Houcine akhnif
3 Sep 2021 Reviewed Reviewer Report - Heber Gomez Malave
7 Oct 2021 Reviewed Reviewer Report - Arkalgud Ramaprasad
7 Oct 2021 Reviewed Reviewer Report - Yoseph Abraha
7 Nov 2021 Author responded Author comments - Cong Huang
Resubmission - Version 2
7 Nov 2021 Submitted Manuscript version 2
23 Nov 2021 Reviewed Reviewer Report - El Houcine akhnif
24 Nov 2021 Reviewed Reviewer Report - Arkalgud Ramaprasad
24 Nov 2021 Reviewed Reviewer Report - Heber Gomez Malave
2 Dec 2021 Author responded Author comments - Cong Huang
Resubmission - Version 3
2 Dec 2021 Submitted Manuscript version 3
9 Dec 2021 Reviewed Reviewer Report - El Houcine akhnif
19 Dec 2021 Reviewed Reviewer Report - Arkalgud Ramaprasad
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
20 Dec 2021 Editorially accepted
3 Jan 2022 Article published 10.1186/s12961-021-00810-1

You can find further information about peer review here.

Back to article page